Secondary glaucoma including exfoliation glauocma, uveitic glaucoma and steroid-induced glaucoma.
Conditions
Interventions
0.4% ripasudil ophthalmic solution. twice daily. for 6 months.
Sponsors
Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Secondary glaucoma patients who need additional IOP reduction therapy will be recruited, when prior anti-glaucoma ophthalmic solution do not respond efficiently.
Exclusion criteria
Exclusion criteria: 1) Contraindicated for use in ripasudil. 2) Patients whose MD value in Humphrey visual field examination (program SITA-standard 24-2) is -12 dB or less. 3) Patient with poor best corrected visual acuity (less than 20/40). 4) Patient with severe refractive error (over +9.0 D or below -9.0 D). 5) Eye with over 3.0 D difference of spherical equivalent power compared to fellow eye. 6) Patients with the corneal disorder to inhibit accurate IOP measurement by Goldmann applanation tonometer. 7) Patients with poor mydriasis and whose optic disc is unobservable. 8) Eyes that had undergone intraocular surgery or intraocular laser therapy. However, the eyes that underwent cataract surgery after a lapse of 6 months could be included. 9) Eyes with a history of ocular trauma. 10) Patients with the retinal disorder which influences visual field. 11) Patients with the optic nerve disorder or intracranial disease which influences visual field. 12) Patients who is rejected as unsuitable case for this study by principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of intraocular pressure between at baseleine and at 6-month follow-up period. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Comparison of intraocular pressure (IOP) between at baseleine and at each follow-up period (1-, 2-, 3-, and 6-month). 2) Relationship between IOP reduction and inflammation severelity in uveitic glaucoma patients. 3) Detection of predictive factors for IOP reduction effects. 4) Frequency of adverse events. | — |
Countries
Japan
Contacts
Public ContactKana Nakamoto
Institute for Clinical Effectiveness ROCK-S Study Office
Outcome results
None listed